Andere Sprachen Scandion Oncology A/S

Aktien

A2N9BV

DK0061031895

SCOL

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 12:53:39 30.04.2024			% 5 Tage	% 1. Jan.
1,345 ^SEK	-3,93 %		-6,92 %	-66,33 %

21.03.	Scandion Oncology berichtet aktualisierte Phase II Corist-Daten, einschließlich Topline-Gesamtüberlebensrate	CI
07.03.	Scandion Oncology meldet zweites bestätigtes teilweises Ansprechen in der Phase IIa CORIST Teil 3-Studie	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Scandion Oncology – Notice convening the Annual General Meeting	19.04.
Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival	21.03.
Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival	21.03.
Scandion Oncology - Annual Report 2023	15.03.
Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial	07.03.
Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial	07.03.
Scandion Oncology Q4 2023 - Striving towards randomised controlled data	01.03.
Scandion Oncology – Q4 & yearend report 2023	28.02.
Scandion Oncology A/S Reports Earnings Results for the Full Year Ended December 31, 2023	28.02.
Scandion Oncology A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.02.
Invitation to Scandion Oncology webcast and conference call February 28, 2024	22.02.
Scandion Oncology reports positive topline Phase IIa data from the CORIST Part 3 trial	31.01.
Scandion Oncology Reports Positive Topline Phase IIa Data from the CORIST Part 3 Trial	31.01.
Scandion Oncology receives Notice of Allowance for patent to enhance US patent exclusivity on SCO-101	05.01.
Scandion Oncology Receives Notice of Allowance for Patent to Enhance US Patent Exclusivity on SCO-101	05.01.
CORIST part 3 topline data are expected in the second half of January 2024	21.12.
Scandion Oncology Announces Presenting Topline Data in the Ongoing Corist Part 3 Study	21.12.
Scandion Oncology identifies potentially effective treatment of gastric cancer	15.12.
Scandion Oncology Completes Pre-Clinical Studies and Identifies Potentially Effective Treatment of Gastric Cancer	15.12.
Scandion Oncology Obtains Patent for Combination Cancer Treatment Drug	29.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Scandion Oncology A/S

Aktien

A2N9BV

DK0061031895

SCOL

Andere Sprachen

Filter